Octanine (Human Coagulation Factor Ix)

The factor IX in Octanine binds to activated factor X on platelet surfaces, forming the intrinsic tenase complex that accelerates conversion of factor X to factor Xa, thereby restoring thrombin generation and enabling normal clot formation in individuals lacking functional factor IX.

The prescribed dose of Octanine is individualized by the treating physician based on the patient’s weight, severity of factor IX deficiency, bleeding severity, and target factor IX activity levels; exact regimens are not publicly standardized.

Safety data for Octanine in pregnancy and lactation are limited; clinicians should weigh potential benefits against risks and consider alternative management strategies, as factor IX products cross the placenta and may be present in breast milk.

To order Octanine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Octanine is a recombinant factor IX concentrate similar in efficacy to other licensed recombinant products, offering a purified intravenous formulation. Differences among products may include manufacturing processes, specific activity, stability profiles, and approved indications, which clinicians evaluate when selecting therapy.

Octanine should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter and ensure the vial is within its expiry date.

Octanine is given as an intravenous infusion, typically diluted in a compatible solution and administered slowly under clinical supervision, with dosing adjusted according to factor IX activity monitoring.

Serious risks include the development of neutralizing inhibitors against factor IX, severe allergic reactions such as anaphylaxis, and rare thromboembolic events, all of which require immediate medical attention.

Octanine is contraindicated in patients with known hypersensitivity to any component of the product, including the recombinant protein or excipients, and in individuals who have previously developed severe allergic reactions to factor IX concentrates.